Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on August 30, 2007

Stroke. 2007
Published online before print August 30, 2007, doi: 10.1161/STROKEAHA.107.486217
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/10/2804    most recent
STROKEAHA.107.486217v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, L.-R.
Right arrow Articles by Kessler, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, L.-R.
Right arrow Articles by Kessler, J. A.
Related Collections
Right arrow Animal models of human disease
Right arrow Other Stroke Treatment - Medical

Submitted on February 28, 2007
Accepted on March 22, 2007

Beneficial Effects of Hematopoietic Growth Factor Therapy in Chronic Ischemic Stroke in Rats

Li-Ru Zhao MD, PhD*; Hector H. Berra PhD; Wei-Ming Duan MD, PhD; Seema Singhal MD; Jayesh Mehta MD; A. Vania Apkarian PhD; and John A. Kessler MD

From the Departments of Neurology (L.R.Z., J.A.K.), Physiology (H.H.B., A.V.A.), and Medicine (S.S., J.M.), Northwestern University, Feinberg School of Medicine, Chicago, Ill; and the Departments of Cellular Biology and Anatomy (L.R.Z., W.M.D.), and Neurology (L.R.Z.), Louisiana State University Health Sciences Center, Shreveport, La.

* To whom correspondence should be addressed. E-mail: lzhao{at}lsuhsc.edu.

Background and Purpose—Stroke is the leading cause of adult disability worldwide. Currently, there is no effective treatment for stroke survivors. Stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) are the growth factors regulating hematopoiesis. We have previously observed that SCF and G-CSF have neuroprotective and functional effects on acute brain ischemia. In the present study, the beneficial effects of SCF and G-CSF on chronic brain ischemia were determined.

Methods—SCF, G-CSF, or SCF+G-CSF was administered subcutaneously to rats 3.5 months after induction of ischemic stroke by middle cerebral artery occlusion. Neurological deficits were evaluated by limb placement test and foot fault test over time. Field-evoked potential was performed 19 weeks after treatment. Infarct volume was histologically determined using serial coronal sections.

Results—Significant functional improvement was seen in SCF+G-CSF-treated rats 1, 5, and 17 weeks after injections. SCF alone also improved functional outcome, but it did not show as stable improvement as SCF+G-CSF. No functional benefit was seen in G-CSF-treated rats. Field-evoked potential studies further confirmed the behavioral data that the normal pattern of neuronal activity was reestablished in the lesioned brain of the rats with good functional outcome. Interestingly, infarction volume was also significantly reduced in SCF+G-CSF-treated rats.

Conclusion—These data provide first evidence that functional restoration in chronic brain ischemia can be attained using hematopoietic growth factors.


Key words: animal models • cerebral infarction • chronic stroke • functional recovery • treatment




This article has been cited by other articles:


Home page
StrokeHome page
J. Minnerup, J. Heidrich, J. Wellmann, A. Rogalewski, A. Schneider, and W.-R. Schabitz
Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of Focal Cerebral Ischemia
Stroke, June 1, 2008; 39(6): 1855 - 1861.
[Abstract] [Full Text] [PDF]